A MARKOV MODEL EVALUATING THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO VEDOLIZUMAB FOR PATIENT'S WITH CROHN'S DISEASE AS THIRD-LINE THERAPY

被引：1
|
作者：
Schneider, Yecheskel
Saumoy, Monica
Cohen-Mekelburg, Shirley A.
Gold, Stephanie
Scherl, Ellen
Steinlauf, Adam F.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)32115-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1899
引用
收藏
页码：S589 / S589
页数：1
相关论文
共 50 条
  • [1] The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn?s disease
    Macaluso, Fabio Salvatore
    Grova, Mauro
    Saladino, Marica
    Cappello, Maria
    Demarzo, Maria Giulia
    Privitera, Antonino Carlo
    Giangreco, Emiliano
    Garufi, Serena
    Renna, Sara
    Casa, Angelo
    Ventimiglia, Marco
    Fries, Walter
    Orlando, Ambrogio
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (04) : 471 - 477
  • [2] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [3] The Effectiveness of Ustekinumab and Vedolizumab as Third-line Therapy in Patients with Refractory Crohn's Disease
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I359 - I359
  • [4] THE EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB AS THIRD-LINE THERAPY IN PATIENTS WITH REFRACTORY CROHN'S DISEASE
    Macaluso, F. S.
    Grova, M.
    Saladino, M.
    Demarzo, M. G.
    Privitera, A. C.
    Giangreco, E.
    Garufi, S.
    Renna, S.
    Casa, A.
    Ventimiglia, M.
    Cappello, M.
    Fries, W.
    Orlando, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2022, 54 : S93 - S94
  • [5] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES
    Zouraq, Azzabi, I
    Wilson, M.
    Hather, G.
    Curtis, R.
    Luo, M.
    Khalid, J. M.
    Minda, K.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [6] Cost-Effectiveness of Vedolizumab Compared to Adalimumab for Patients with Crohn's Disease Aft er Loss of Response to Infliximab: A Markov Model
    Schneider, Yecheskel
    Saumoy, Monica
    Gold, Stephanie L.
    Cohen-Mekelburg, Shirley
    Bosworth, Brian
    Scherl, Ellen J.
    Steinlauf, Adam
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S335 - S336
  • [7] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY IN PATIENTS WITH CROHN'S DISEASE IN THE UNITED KINGDOM (UK)
    Robson, R. E.
    Vanoli, A.
    Tolley, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S455 - S456
  • [8] Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
    Amanda Hansson-Hedblom
    Chrissy Almond
    Fredrik Borgström
    Indeg Sly
    Dana Enkusson
    Anders Troelsgaard Buchholt
    Linda Karlsson
    [J]. Cost Effectiveness and Resource Allocation, 16
  • [9] Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
    Hansson-Hedblom, Amanda
    Almond, Chrissy
    Borgstrom, Fredrik
    Sly, Indeg
    Enkusson, Dana
    Buchholt, Anders Troelsgaard
    Karlsson, Linda
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [10] COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY
    Wilson, M.
    Lucas, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S145 - S145
12345